Health Care & Life Sciences Consulting

Overview

As a stakeholder in the health and life sciences industry, you work every day to extend the boundaries of human health and enhance patient care. With a bipartisan team of lobbyists and public policy professionals, we partner with you to advance this mission through effective coalition management, strategic communications, and strong relationships with decision-makers at the state and federal levels. We promote the public policy and advocacy agendas of hospitals and health systems, academic medical centers, medical device and life science companies, patient advocacy organizations, membership trade associations, health professional societies, and global health groups. With our guidance, clients author and enact legislation; establish new policies and programs; navigate and shape regulatory processes; secure and maintain Medicare reimbursement for new products and technologies; defeat proposals that threaten their priorities; and take action to safeguard their interests. We build bridges with agencies such as the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) to help clients secure funding and support for their projects, campaigns, and research initiatives. Our team unites diverse stakeholders in coalitions aligned under shared policy goals, develops politically viable policy solutions that advance client goals, and builds awareness and support through grassroots advocacy. We’ve helped clients shape legislative, executive branch, and regulatory activity at the highest level.

Faegre Drinker Consulting professionals do not act as attorneys for clients. Learn more about the Faegre Drinker Consulting practice.

Insights & Events

Latest

最新 May 2026

MSO-PC Structures in the Crosshairs: California AG Takes Aim at Continuity Agreements

Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625 (Cal. Ct. App. Mar. 30, 2026)
7 min read
最新 April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
最新 March 2026

Access through Innovation with Amazon Pharmacy

Digital Health “From the Inside Out” Leadership Series
2 min read
最新 March 2026

FDA Finalizes Rule Requiring 12-Digit National Drug Code (NDC)

Two Little Digits, One Very Big Operational Headache
4 min read
最新 February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
媒体报道 January 2026

Nick Manetto Discusses Future of Federal PBM Spread Pricing Bill With Inside Health Policy

1 min read
Speaking Engagement Recap September 01, 2025

Better Together Starts With Being Whole Alone

The HX Experience Podcast
1 min read
Speaking Engagement Recap September 01, 2025

Family is a System, Not a Solo Act

The HX Experience Podcast
1 min read
News October 2023

Diane Marasiu Carter Receives Government Affairs Society of Indiana ‘Allen C. Steere Award’

1 min read
Press Release April 2023

Pharmaceutical Industry Advocate Theresa Frangiosa Strengthens Faegre Drinker Consulting in Washington, D.C.

2 min read
Insights
最新 May 2026

MSO-PC Structures in the Crosshairs: California AG Takes Aim at Continuity Agreements

Art Center Holdings, Inc. v. WCE CA Art, LLC, No. B338625 (Cal. Ct. App. Mar. 30, 2026)
7 min read
最新 April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
最新 March 2026

Access through Innovation with Amazon Pharmacy

Digital Health “From the Inside Out” Leadership Series
2 min read
最新 March 2026

FDA Finalizes Rule Requiring 12-Digit National Drug Code (NDC)

Two Little Digits, One Very Big Operational Headache
4 min read
最新 February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
媒体报道 January 2026

Nick Manetto Discusses Future of Federal PBM Spread Pricing Bill With Inside Health Policy

1 min read
媒体报道 January 2026

Megan Herber and Nisha Quasba Discuss Reintroduction of NSGC’s Genetic Counseling Bill

2 min read
最新 November 2025

What Does the Agreement to Reopen the Federal Government Mean for Health Policy Interests?

And What Opportunities May Lie Ahead?
5 min read
最新 November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
媒体报道 October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read

Meet The Team

Meet The Team